EphA2-targeted CAR-T Cells

EphA2-targeted CAR-T cells represent an innovative immunotherapy approach that utilizes a patient's own T-cells, genetically engineered to express chimeric antigen receptors (CARs). These CARs are specifically designed to recognize and bind to the EphA2 (Ephrin type-A receptor 2) protein, which is frequently overexpressed on the surface of various cancer cells, including glioblastoma, non-small cell lung cancer, osteosarcoma, Ewing sarcoma, and esophageal squamous cell carcinoma, while exhibiting limited expression in healthy tissues. Upon binding to EphA2 on tumor cells, the CAR-T cells become activated, initiating a cascade that leads to the direct lysis and destruction of cancer cells. This activation also triggers the release of potent pro-inflammatory cytokines, such as interferon-gamma (IFN-γ) and tumor necrosis factor-alpha (TNF-α), further contributing to the anti-tumor immune response. This therapeutic strategy aims to harness the precision and power of the immune system to specifically target and eliminate EphA2-positive solid tumors.

Other names

EphA2-redirected CAR T-cellsEphA-2-redirected CAR T-cellsEphA 2-redirected CAR T-cellsEphA2-specific CAR-T cellsEphA-2-specific CAR-T cellsEphA 2-specific CAR-T cells